Healthcare / BiotechnologyASX
$0.01
-0.00 (-8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-3.2M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$42M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-283.2%
↓Gross Margin
71.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.1%
FCF CAGR
—
FCF margin
88.6%
FCF / Net income
-0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.2M · net income $-4.4M · FCF $1.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2M | $1.2M | $1.1M | $473551.00 | $1.2M |
| Net Income | $-4.4M | $-4.4M | $-3.1M | $-3.4M | $-2.3M |
| EBITDA | $-3.8M | $-3.8M | $-2.9M | $-3.2M | $-2.1M |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Gross Margin | 71.9% | 71.9% | 59.3% | -9.2% | 72.1% |
| Operating Margin | -481.7% | -481.7% | -437.8% | -1006.8% | -247.6% |
| Net Margin | -354.7% | -354.7% | -275.6% | -725.7% | -194.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.33 | 0.03 | 0.10 |
| Current Ratio | 9.95 | 9.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.1M | $1.1M | $-4.0M | $-3.2M | $-1.7M |
| Returns | |||||
| ROE | -283.2% | -283.2% | -95.5% | -53.9% | -95.6% |
| Valuation | |||||
| P/B | 23.04 | 23.04 | 2.86 | 1.24 | 9.75 |
| Growth & Yield | |||||
| Revenue Growth | 9.9% | 9.9% | 139.2% | -60.7% | — |
| EPS Growth | -40.0% | -40.0% | 33.3% | -15.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+120.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+120.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.